Amgen’s cost-cutting showed results yesterday, as the company managed to increase its first-quarter earnings even as it continued to take a beating on its anemia drugs.
Earnings were up 2.3% year over year, while sales of anemia fighters Aranesp and Epogen were off 25% and 11%, respectively.
With the company’s stock way down (see chart) and a [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment